Network Pharmacology Analysis on Mechanism of Jian Pi Qing Gan Yin Decoction Ameliorating High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease and Validated in Vivo.

Weiwei Liu,Jingyu Shang,Yinxiang Deng,Xiuzhen Han,Yugen Chen,Shuangshuang Wang,Ruwen Yang,Fan Dong,Hongtao Shang
DOI: https://doi.org/10.1016/j.jep.2022.115382
IF: 5.195
2022-01-01
Journal of Ethnopharmacology
Abstract:Ethnopharmacological relevance: Jian Pi Qing Gan Yin (JPQGY) has been used clinically to relieve non-alcoholic fatty liver disease (NAFLD) in China for decades; however, the underlying mechanisms of JPQGY remain unclear. Aim of the study: We evaluated the effects and mechanisms of JPQGY and hepatic steatosis caused by the middle stage of 13-week-high-fat-diet-induced NAFLD in mice.Materials and methods: Different dosages of JPQGY (5.5, 11, and 22 g/kg/day) were administered to NAFLD mice simultaneously. Body weight, body mass index (BMI), and liver lipid-and inflammation-related serum indicators were measured enzymatically. Liver samples were stained with Oil Red O and hematoxylin and eosin (H&E). Next, we performed a network pharmacology analysis and verified eight target genes mapping to NAFLD-related lipid metabolism pathways. The mRNA/protein expression was analyzed by real-time polymerase chain reaction (PCR) and western blotting.Results: JPQGY significantly relieved histological damage (steatosis-inflammation-fibrosis), prevented the downregulation of AMPK and Ppar alpha, and upregulated LXR alpha, Srebp-1c, F4/80, Nf-Kappa b, and Cyp2e1 in the HFDinduced NAFLD mouse model.Conclusions: The present results suggest that chronic treatment with JPQGY ameliorated HFD-induced NAFLD in mice by targeting the first and second phases of hepatic steatosis by stimulating the AMPK/PPAR alpha pathway and inhibiting the LXR alpha/Srebp1/Nf-Kappa b pathway. Our findings provide evidence that supports the clinical use of this formula for high-fat diet-induced fatty liver disease.
What problem does this paper attempt to address?